The potential role of ERβ isoforms in the clinical management of breast cancer

被引：19

作者：

Green, C. A. ^{[2
]}

Peter, M. B. ^{[2
]}

Speirs, V. ^{[2
]}

Shaaban, A. M. ^{[1
]}

机构：

[1] St James Univ Hosp, St Jamess Inst Oncol, Dept Histopathol & Mol Pathol, Leeds LS9 7TF, W Yorkshire, England

[2] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Leeds LS2 9JT, W Yorkshire, England

来源：

HISTOPATHOLOGY | 2008年 / 53卷 / 04期

关键词：

breast cancer; ER beta isoforms; oestrogen receptors; prognosis; tamoxifen;

D O I：

10.1111/j.1365-2559.2008.02968.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The discovery of a second oestrogen receptor, ER beta, was a subject of much interest, as this suggested a means to improve the prognostic stratification of invasive breast cancer, better predict response to endocrine therapy, develop new chemotherapeutic/chemopreventative drugs and perhaps prevent inappropriate treatment. However, this has not proved to be straightforward with the discovery of five ER beta isoforms and numerous exon deletion variants. This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings.

引用

页码：374 / 380

页数：7

共 55 条

[1]

Allred DC, 1998, MODERN PATHOL, V11, P155

[2] A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer [J].